The Ophthalmic Drugs Market: 2021 – 2030 – Opportunities, Challenges, Strategies & Forecasts

Release Date: May 2021
Number of Pages: 335
Number of Tables and Figures: 46

As a higher percentage of the global population lives longer, age related eye disorders such as glaucoma, diabetic retinopathy, cataracts and macular degeneration are on the rise. In addition, a host of modern lifestyle habits such as poor eating, overworking and the excessive use of visual displays, have created an environment rife with conditions such as dry eye syndrome and myopia.
Although surgery is the only option for the treatment of certain ophthalmic conditions such as cataracts, ophthalmic drugs continue to account for the highest percentage of spending within the wider market for ophthalmic products. Expected to surpass $39 Billion in global spending by the end of 2021, ophthalmic drugs remain the preferred approach to treat common eye disorders, ranging from dry eye syndrome to more complicated conditions such as macular degeneration. Despite the loss of patent protection for several blockbuster drugs which has attracted generic competition, the market is ripe for future growth with several novel products in late-stage development. Product launches in 2021 will be across all major disease areas in ophthalmology including: macular degeneration, intraocular lens implants, dry eye, and glaucoma.
The “Ophthalmic Drugs Market: 2021 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the ophthalmic drugs ecosystem including application areas, delivery technologies, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline,  opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for ophthalmic drugs from 2021 through to 2030. The forecasts are segmented for over 7 therapeutic categories, 5 regions and 25 leading countries. The report covers 133 ophthalmic drugs in the developmental pipeline across 5 therapeutic categories.    
​
The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report, as well as an Excel sheet covering clinical drug developmental pipeline for ophthalmic drugs.
For a Sample and Table of Contents please contact [email protected]

Pricing: The report is available for the following price: 

Single User License: USD 2,500

Company Wide License (Single Site): USD 3,500
​
Company Wide License (Global Site): USD 6,500

Key Findings:
The report has the following key findings: 
  • Expected to surpass $39 Billion in global spending by the end of 2021, ophthalmic drugs remain the preferred approach to treat common eye disorders, ranging from dry eye syndrome to more complicated conditions such as glaucoma and macular degeneration.
  • Drug developers are continuing to invest heavily in drug development programs for eye disorders, primarily in the areas of AMD (Age-Related Macular Degeneration), diabetic eye disease, glaucoma, dry eye syndrome. These indications collectively approximately constitute 75% of all clinical development programs.
  • Late-stage clinical development programs are primarily focused on long-acting VEGF inhibition for wet AMD, and other vascular retinal disorders;  anti-integrin therapy for diabetic eye disease; anti-complement agents for dry AMD; novel ROCK & other protein kinase inhibitors, and prostaglandin EP2, EP3 & FP receptor agonists for glaucoma; RASP (Reactive Aldehyde Species), nicotinic acetylcholine and cardiolipin peroxidation inhibition for dry eye syndrome; as well as product candidates based on new formulations and delivery mechanisms for existing drugs.
  • Several novel approaches to ophthalmic drug delivery are beginning to emerge – ranging from implants for the sustained release of medication over a period of months to precise micro-dosing technologies that alleviate the inefficiencies associated with the high doses delivered by conventional eye droppers.

Topics Covered:
The report covers the following topics: 
  • Ophthalmic drugs ecosystem
  • Market drivers and barriers
  • Role of drugs in ophthalmology and key trends
  • Analysis of key drug classes and leading ophthalmic drugs
  • 133 Ophthalmic pipeline candidates across 5 therapeutic categories.
  • Advanced drug delivery technologies
  • Future roadmap and value chain
  • Profiles and strategies of over 170 leading ecosystem players, including ophthalmic drug developers
  • Strategic recommendations for ecosystem players
  • Market analysis and forecasts from 2021 till 2030

Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:

Therapeutic Categories
  • Anti-Infectives
  • Allergy & Anti-Inflammatory
  • Dry Eye
  • Glaucoma
  • AMD
  • Diabetic Eye Disease
  • Other Disorders

Regional Markets
  • Asia Pacific
  • Europe
  • Middle East & Africa
  • North America
  • Latin & Central America

Country Markets
  • Brazil
  • Canada
  • China
  • Egypt
  • France
  • Germany
  • Greece
  • India
  • Israel
  • Italy
  • Japan
  • Mexico
  • Netherlands
  • Poland
  • Portugal
  • Russia
  • Saudi Arabia
  • South Africa
  • South Korea
  • Spain
  • Switzerland
  • Taiwan
  • Turkey
  • UK
  • USA

Key Questions Answered:
The report provides answers to the following key questions:
  • How big is the ophthalmic drugs opportunity?
  • What trends, challenges and barriers are influencing its growth?
  • How is the ecosystem evolving by segment and region?
  • What will the market size be in 2025, and at what rate will it grow?
  • Which countries and submarkets will see the highest percentage of growth?
  • What are the prospects of advanced drug delivery technologies for ophthalmology?
  • How will next-generation anti-VEGF therapies, ROCK (Rho Kinase) inhibitors, anti-complement agents and other new drug classes impact the eye disorder treatment landscape?
  • Who are the key market players, and what are their strategies?
  • How will patent expirations of innovator drugs impact the market?
  • What strategies should ophthalmic drug developers adopt to remain competitive?

List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:
4D Molecular Therapeutics
AC Immune
Acorn Biomedical
Acucela
Adenovir Pharma
Adverum Biotechnologies
Aerie Pharmaceuticals
Aerpio Pharmaceuticals
AIRM (Astellas Institute for Regenerative Medicine)
Akorn Pharmaceuticals
Aldeyra Therapeutics
Alimera Sciences
Allegro Ophthalmics
Allergan
Allysta Pharmaceuticals
Altacor
Alteogen
Amarantus Bioscience Holdings
Amgen
Amorphex Therapeutics
Ampio Pharmaceuticals
Annexon Biosciences
Apellis Pharmaceuticals
Astellas Pharma
AVX Pharma
Bausch + Lomb
Bayer
Benitec Biopharma
Bial
Bicycle Therapeutics
BioAxone Biosciences
BioDiem
Bioeq IP
BioLight Life Sciences
BioLineRx
Bionure Farma
BioTime
BMS (Bristol-Myers Squibb)
Catalyst Biosciences
Cell Cure Neurosciences
Chengdu Kanghong Pharmaceuticals Group
Chong Kun Dang Pharmaceutical Corporation
Chugai Pharmaceutical Company
Clearside Biomedical
Coherus BioSciences
Colby Pharmaceutical Company
D.Western Therapeutics Institute
DHP KOREA
Dompé Farmaceutici
Elsalys Biotech
Euclid Systems Corporation
EyeGate Pharmaceuticals
Eyenovia
EyePoint Pharmaceuticals
EyeRx Research
Eyevance Pharmaceuticals
Eyevensys
FCDI (FUJIFILM Cellular Dynamics, Inc.)
Focus Laboratories
Formycon
Galapagos
Gene Signal
Gensight Biologics
Glaukos Corporation
Glycadia Pharmaceuticals
Graybug Vision
GSK (GlaxoSmithKline)
Handok
Healios
Hebrew University of Jerusalem
Helvetic BioPharma
HitGen
iCo Therapeutics
Iconic Therapeutics
ID Pharma Co.
InMed Pharmaceuticals
Intas Pharmaceuticals
Ironwood Pharmaceuticals
Isarna Therapeutics
Johnson & Johnson Vision
Kala Pharmaceuticals
KalVista Pharmaceuticals
Kissei Pharmaceutical
Kodiak Sciences
Kowa Company
Kubota Pharmaceutical Holdings
Kyoto Prefectural University of Medicine
Laboratorios SALVAT
Laboratorios Sophia
Lee's Pharmaceutical Holdings
Lexicon Pharmaceuticals
Lubris BioPharma
MacuCLEAR
Mallinckrodt
MANF Therapeutics
Mannin Research
Mati Therapeutics
MC2 Therapeutics
Merck & Co.
MimeTech
Mimetogen Pharmaceuticals
Mitotech
Molecular Partners
MorphoSys
Mundipharma International
Nanyang Technological University
NEMUS Bioscience
NeuBase Therapeutics
NeuMedics
Neuregenix
Neurim Pharmaceuticals
Neurotech Pharmaceuticals
Nicox
NoNo
NovaBay Pharmaceuticals
Novaliq
Novartis
Novelion Therapeutics
NovelMed Therapeutics
OcuCure Therapeutics
Ocugen
Ocular Therapeutix
Oculis
OcuNexus Therapeutics
Ohr Pharmaceutical
Omeros Corporation
Oncolys BioPharma
ONL Therapeutics
Ono Pharmaceutical
Ophthotech Corporation
Opthea
Otero Therapeutics
Otsuka Holdings
Otsuka Pharmaceutical Company
Oxford BioMedica
Oxurion
Oyster Point Pharma
PanOptica
Parion Sciences
Peregrine Ophthalmic
Perrigo Company
Pfenex
Pfizer
pH Pharma
PharmaMar
Phio Pharmaceuticals Corporation
Pivot Pharmaceuticals
Q BioMed
Quark Pharmaceuticals
Radikal Therapeutics
Recordati
Regeneron Pharmaceuticals
RegeneRx Biopharmaceuticals
REGENXBIO
Replenish
Rigel Pharmaceuticals
Roche Holding (F. Hoffmann-La Roche)
Rocket Pharmaceuticals/Inotek Pharmaceuticals
Sandoz
Sanofi
Santen Pharmaceutical Company
SciFluor Life Sciences
Seikagaku Corporation
Senju Pharmaceutical Company
Sesen Bio
Shire
SPARC (Sun Pharma Advanced Research Company)
Spark Therapeutics
STADA Arzneimittel
Stealth BioTherapeutics
Stemedica Cell Technologies
Sumitomo Dainippon Pharma
Sun Ophthalmics
Sun Pharma (Sun Pharmaceutical Industries)
Sylentis
Taejoon Pharm
Taiho Pharmaceutical Company
Takeda Pharmaceutical Company
Teva Pharmaceutical Industries
THÉA Laboratories
TikoMed
TopiVert
TRACON Pharmaceuticals
Tyrogenex
U.S. FDA (Food and Drug Administration)
Ube Industries
Valeant Pharmaceuticals International
Vision Medicines
Wakamoto Company
Wize Pharma
Xbrane Biopharma
Yissum Research Development Company